Systemic administration of epidermal growth factor (EGF) in neonatal rats
results in reduced body weight gain and decreased circulating levels of
IGF-I, suggesting its involvement in EGF-induced growth retardation. We
investigated the effect of EGF and/or IGF-I administration for 7 days on
circulating IGF-I and IGFBP levels and hepatic and renal IGF-system mRNA
expression profiles in adult female rats. EGF administration (30
microg/rat/day) did not influence body weight, liver or kidney weight. In
contrast, IGF-I (400 microg/rat/day) and EGF/IGF-I administration
increased both body weight and kidney weight. Also, serum IGF-I and the 30
kDa IGFBPs (IGFBP-1 and -2) were significantly increased in these groups.
Serum IGFBP-3 levels increased in the IGF-I group along with increased
hepatic IGFBP-1 and -3 mRNA levels. In contrast, in the EGF administration
group serum IGFBP-3 levels were significantly decreased; however, the mRNA
levels remained unchanged. In the EGF/IGF-I administration group, serum
IGF-I and IGFBP-3 levels were significantly lowered when compared with the
IGF-I administration group. This was in contrast to the effect on kidney
weight increase that was identical for the IGF-I and EGF/IGF-I groups. The
decrease in serum IGFBP-3 was not reflected at the hepatic IGFBP-3 mRNA
level. IGFBP-3 expression might be regulated at a post-transcriptional
level although EGF induced IGFBP-3 proteolysis could not be demonstrated
in vitro. We conclude that EGF administration reduced serum IGFBP-3
whereas IGF-I administration increased the level of IGFBP-3 and IGF-I and
resulted in an increased body and kidney weight in adult female rats